Researcher Profile Form First National Pediatric Brain Tumor Research Meeting March 9, 2025 - Jerusalem
Researcher: Dr. Hilla Ben Hamo
Current Role & Affiliation
Title/Position: CEO & Co-Founder at MeNow
Institution: MeNow - AI-Driven Natural Ingredient Discovery & Prediction of activity
Email: hillaarbel@gmail.com
Phone: 052-5205043
Dr. Hilla Ben Hamo is the CEO and founder of MeNw company. She is currently leading an effort to expand the scope of research of the company to the field of oncology through new collaborations with researchers in the field.
Research Focus
Bioactives are natural substances that exert a positive impact on living organisms. In spite of their high potential, less than 1% of bioactives have been identified. MeNow, technology involves discovery of new bioactives. By analyzing massive molecular datasets and predicting interactions at a systems biology level, WeNow uncovers combinations that maximize performance, safety, and sustainability in product formulations. for the development of innovative functional ingredients.
Current Projects Related to Pediatric Brain Tumors
Current focus of MeNow company is on bioactives preventing UV dammage based on cyclophilin D activity inhibition, inhibition of nitric oxide synthase (NOS) activity and stimulation of SIRT1 activity.
Laboratory/Research Resources
A unique AI technology
Collaboration Interests
use of the MeNow AI technology to predict possible synergism and expected efficacy of cancer therapeutics
Keywords
AI , drug design, targeted therapy ,cancer therapeutics
Brief Bio
Hilla Ben Hamo, based in Tel Aviv-Yafo, IL, is currently a Chief Executive Officer and Co-Founder at Menow. Hilla Ben Hamo brings experience from previous roles at Pomicell Personally Optimized Medical Intelligence, Alvit LCS Pharma and Nrgene Ltd.. Hilla Ben Hamo holds a 2011 - 2015 Doctor of Philosophy in Medical Engineering @ Ben - Gurion University Of The Negev.
